[C-11]NOP-1A and Alcohol Use Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-27

Study Completion Date

2021-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to compare \[C-11\]NOP-1A binding in recently abstinent alcohol use disorders and controls

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Medication Development in Alcoholism: Acamprosate Versus Naltrexone

NCT00656630

Alcoholism

COMPLETED PHASE2

The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion

NCT00667771

Alcohol Dependence Alcoholism

COMPLETED EARLY_PHASE1

A Novel Human Lab Model for Screening AUD Medications

NCT04249882

Alcohol Use Disorder

COMPLETED PHASE2

Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking

NCT00183222

Alcohol Dependence

COMPLETED PHASE2

Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation

NCT02639273

AUD

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will allow for understanding brain stress and antistress mechanisms that underlie abuse of alcohol in humans

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

\[C-11\]NOP-1A

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Alcohol use disorders

\[C-11\]NOP-1A PET Scan

Group Type EXPERIMENTAL

[C-11]

Intervention Type RADIATION

Radiolabel

NOP-1A

Intervention Type DRUG

Tracer

Controls

\[C-11\]NOP-1A PET Scan

Group Type EXPERIMENTAL

[C-11]

Intervention Type RADIATION

Radiolabel

NOP-1A

Intervention Type DRUG

Tracer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[C-11]

Radiolabel

Intervention Type RADIATION

NOP-1A

Tracer

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or Females
2. Fulfill DSM5 diagnosis for alcohol use disorder
3. Medically Healthy

1. Males or females
2. Absence of present or past psychiatric conditions (including alcohol or drug use disorders)
3. Medically Healthy

Exclusion Criteria

1. Pregnancy or lactation
2. Comorbid severe/major medical, psychiatric (such as bipolar and psychotic disorders, etc.,) and current comorbid drug use disorders (other than tobacco use and recreational marijuana use)
3. Metal implants or paramagnetic objects contained within the body which may interfere with MRI scans
4. Currently employed as a radiation worker, or participation in radiation drug research procedures within the previous year
5. Currently on any psychotropic medications that can influence nociceptin transmission in the brain

\[B\]Healthy controls

1. Pregnancy of lactation
2. Medical, psychiatric or comorbid drug/alcohol use disorders
3. Metal implants or paramagnetic objects contained within the body which may interfere with the MRI scan
4. Currently employed as a radiation worker; or participation in radioactive drug research protocols within the previous year
5. Currently on any psychotropic medications that can influence nociceptin transmission in the brain
6. Family history of psychotic disorder, manic episode, drug and alcohol use disorder in first-degree relatives

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes